Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF1 | P36956 | 12/20 | 0.75 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.75 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.75 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27245358 | 0.92 | SREBF1 (0.85) | SREBF1NR1H3NR1H2NPC1RAB9A | |
| SCHEMBL27030601 | 0.91 | SREBF1 (0.89) | SREBF1NR1H3NR1H2NPC1RAB9A | |
| SCHEMBL27030659 | 0.91 | SREBF1 (0.76) | SREBF1NR1H3NR1H2NPC1RAB9A | |
| SCHEMBL29944875 | 0.90 | SREBF1 (0.75) | SREBF1NR1H3NR1H2NPC1RAB9A | |
| SCHEMBL27030433 | 0.90 | SREBF1 (0.75) | SREBF1NR1H3NR1H2NPC1RAB9A | |
| SCHEMBL27030385 | 0.90 | SREBF1 (0.74) | SREBF1NR1H3NR1H2NPC1RAB9A | |
| SCHEMBL29944885 | 0.90 | SREBF1 (0.74) | SREBF1NR1H3NR1H2NPC1RAB9A | |
| SCHEMBL29944865 | 0.89 | SREBF1 (0.73) | SREBF1NR1H3NR1H2NPC1RAB9A | |
| SCHEMBL27030466 | 0.89 | SREBF1 (0.73) | SREBF1NR1H3NR1H2NPC1RAB9A | |
| SCHEMBL27030557 | 0.89 | SREBF1 (0.73) | SREBF1NR1H3NR1H2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| EP-4308554-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | The Board of Trustees of the University of Illinois (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197658-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | SREBF2, SREBF1, SLC2A2 | SREBF1 2/4885NR1H3 21/4885NR1H2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.